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cardial infarction, chest pain greater than 20 minutes and
irregular specifications of EKG. The outcome measured
was reduction in mortality at a 30-day follow-up. The
study was based on a societal perspective, hence the cost
measure included both direct costs such as cost of hospi-
talizations, drug acquisition, follow-up hospitalizations
and physicians’ fees, and indirect costs. We calculated the
effectiveness measure, using life expectancy, as number of
quality-adjusted life-years (QALYs) saved.
RESULTS: The expected total costs of t-PA treatment
were $16,885 and with streptokinase, the expected total
costs were $14,472. The number of QALYs saved for
each therapy were 12.379 years for t-PA and 12.16 years
for streptokinase. The ICE ratio was calculated to be
$11,171 per QALY.
CONCLUSION: Since the ICE ratio of $11,171/QALY is
less than the most popular cut-off ratio of $40,000/QALY,
we concluded that t-PA is more cost-effective than strep-
tokinase in the treatment of acute myocardial infarctions.
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OBJECTIVE: To examine the costs and outcomes associ-
ated with the use of valsartan, an angiotensin II receptor
blocker, compared to six different anti-hypertensive med-
ications as second-line treatment for mild to moderate
hypertension over 12 months.
METHODS: A decision analytic model was developed to
evaluate the costs and outcomes associated with initiating
treatment with seven different anti-hypertensive medica-
tions. A combination of meta-analysis and predictive logis-
tic regression analysis was used to model effectiveness de-
fined as the proportion of patients responding to anti-
hypertensive treatment (response was defined as a reduction
of diastolic blood pressure to below 90 mmHg or a reduc-
tion of greater than 10 mmHg). The meta-analysis was per-
formed on an intent-to-treat basis. Two regression analyses
were used, one to impute a response rate for those studies
where only change in blood pressure was reported and a
second to determine a dose-response relationship for each
comparator. Costs for drugs, laboratory tests, and physician
visits were obtained from publicly available Ontario
sources. The analysis determined the cost per successful re-
sponder at 12 months for each initial comparator.
RESULTS: The analysis demonstrated that treatment
patterns associated with each medication, particularly
laboratory tests, played an important role in the overall
cost and cost-effectiveness of each therapy as opposed to
simply the drug acquisition cost.
CONCLUSIONS: At least two drugs from each class, an-
giotensin receptor blocker, angiotensin converting en-
zyme inhibitor, and calcium channel blocker, were evalu-
ated and no evidence of class effects was seen.
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OBJECTIVE: Determine current clinical practice in the
treatment of mild-to-moderate uncomplicated hyperten-
sion.
METHODS: Delphi panel survey of general practitioners
and cardiologists in the United States. First round: 11
physician responders. Second round: 10 of 11 physicians
responded. Consensus reached in the second round.
Questions addressed the status quo, JNC-VI guidelines,
initial therapy, and second-line therapy.
RESULTS: Diuretics and ACE inhibitors are more fre-
quently prescribed than other drug classes. HCTZ is the
most frequently used diuretic, atenolol and metoprolol
are the most frequently used beta-blockers. A variety of
drugs are prescribed from ACE inhibitors, calcium chan-
nel blockers and angiotensin-II inhibitors. When a pa-
tient is given combination therapy, the second agent is
typically a diuretic. Physicians generally agreed with the
JNC-VI guidelines, except that: 1) more drugs should be
permissible as first-line therapy (seven physicians regu-
larly consider classes other than diuretics or beta-block-
ers as initial therapy), and 2) comorbidities are a major
factor in drug choice and the guidelines do not ade-
quately address this. Follow-up after initiating drug ther-
apy typically occurs at 1 month. New therapies will gen-
erally be titrated upward once or twice (depending on the
drug) before the drug is discontinued due to lack of effi-
cacy. Once a patient’s hypertension is controlled, moni-
toring occurs every 3 to 4 months. It is extremely rare for
a patient to be unresponsive to all five drug classes. Re-
sults from a series of case studies in which physicians
were asked to select the class of medication they would
prescribe depending on the patient’s age, gender, initial
blood pressure, and initial therapy will be presented.
CONCLUSIONS: This study gives researchers insights
into the differences between clinical practice and clinical
guidelines in hypertension treatment.
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